Myeloid-derived suppressor cells: a novel therapeutic target.
Immunotherapy and angiogenic inhibitors, used alone or in combination with chemotherapy, represent two promising cancer treatment programs. Each is limited by myeloid-derived suppressor cells (MDSCs), which accumulate in tumor-bearing hosts. MDSCs inhibit effector T-cell function and thus prevent the formation and execution of an effective antitumor immune response. Recently reported studies have shown that MDSCs also function to promote tumor-dependent angiogenesis as well as tumor metastasis, and to provide tumor resistance to antiangiogenic drugs. Insights into tumor-imposed dynamic changes in bone marrow function and myeloid cell development should fuel novel drug developments and novel applications of drugs currently in use. Such insights suggest that multitargeted receptor tyrosine kinase inhibitors, such as sunitinib, may be useful adjunctive agents for use in immunotherapy trials treating several tumor types.
Ko
Jennifer S
JS
Department of Immunology, Lerner Research Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Bukowski
Ronald M
RM
Fincke
James H
JH
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D040502:Calgranulin B / Q000502:physiology; D006801:Humans; D007167:Immunotherapy; D022423:Myeloid Cells / Q000187:drug effects* / Q000502:physiology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D019089:Stem Cell Factor / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D040502:Calgranulin B; D019089:Stem Cell Factor; D042461:Vascular Endothelial Growth Factor A